James Condulis
Stock Analyst at Stifel
(1.69)
# 3,670
Out of 5,182 analysts
11
Total ratings
44.44%
Success rate
1.1%
Average return
Main Sectors:
Top Industries:
Stocks Rated by James Condulis
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AMLX Amylyx Pharmaceuticals | Initiates: Buy | $21 | $16.36 | +28.36% | 1 | Mar 3, 2026 | |
| AARD Aardvark Therapeutics | Downgrades: Hold | $24 → $6 | $3.94 | +52.28% | 2 | Mar 2, 2026 | |
| NAMS NewAmsterdam Pharma Company | Maintains: Buy | $44 → $50 | $34.76 | +43.84% | 2 | Dec 16, 2025 | |
| XFOR X4 Pharmaceuticals | Maintains: Buy | $7.5 → $10 | $4.10 | +143.90% | 1 | Dec 5, 2025 | |
| CYTK Cytokinetics | Maintains: Buy | $87 → $96 | $65.01 | +47.67% | 2 | Sep 2, 2025 | |
| SLNO Soleno Therapeutics | Maintains: Buy | $74 → $108 | $52.63 | +105.21% | 2 | Mar 28, 2025 | |
| EWTX Edgewise Therapeutics | Initiates: Hold | $30 | $32.82 | -8.59% | 1 | Jan 22, 2025 |
Amylyx Pharmaceuticals
Mar 3, 2026
Initiates: Buy
Price Target: $21
Current: $16.36
Upside: +28.36%
Aardvark Therapeutics
Mar 2, 2026
Downgrades: Hold
Price Target: $24 → $6
Current: $3.94
Upside: +52.28%
NewAmsterdam Pharma Company
Dec 16, 2025
Maintains: Buy
Price Target: $44 → $50
Current: $34.76
Upside: +43.84%
X4 Pharmaceuticals
Dec 5, 2025
Maintains: Buy
Price Target: $7.5 → $10
Current: $4.10
Upside: +143.90%
Cytokinetics
Sep 2, 2025
Maintains: Buy
Price Target: $87 → $96
Current: $65.01
Upside: +47.67%
Soleno Therapeutics
Mar 28, 2025
Maintains: Buy
Price Target: $74 → $108
Current: $52.63
Upside: +105.21%
Edgewise Therapeutics
Jan 22, 2025
Initiates: Hold
Price Target: $30
Current: $32.82
Upside: -8.59%